Cartilage damage in the knee aﬀects millions of people worldwide with a continued rise in incidence. Currently, the only conventional solutions are symptoms (pain, stiﬀness) management, microfracture and in the end, replacing the joint with a prosthesis. Lately, cell therapies have emerged as a solution to regenerate cartilage e.g. tissue engineered autologous chondrocyte implantations (ACIs). However, ACIs often fail to integrate with the surrounding tissue, which results in failure rates up to 36%. Lamina’s new cell therapy from the Strasbourg University and Inserm aims to improve the cell approach by an innovative scaﬀold that houses Mesenchymal stem cells (MSCs) for optimal regeneration of the cartilage. By combining this patented scaﬀold together with growth factors and the MSCs, the product ensures fast recovery and high quality cartilage.
Five recommendations for optimal venture growth in your first six months!
With innovation becoming more and more important in today’s business world; the amount of aspiring entrepreneurs is growing and growing. We at NLC –…
Pressrelease: Concord Neonatal to expand sales internationally
Concord Neonatal, one of the ventures in NLC portfolio, has closed a new funding round, securing substantial funding with private investors. Concord Neonatal is…
Pressrelease: Intelligent ultrasound technique for diagnosing prostate cancer
Tilburg – 18 january 2021 – CbusineZ, the venture capital investor liaised to health insurer CZ, will together with a group of private investors,…